Silvio Danese

87.1k total citations · 30 hit papers
1.3k papers, 50.7k citations indexed

About

Silvio Danese is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Silvio Danese has authored 1.3k papers receiving a total of 50.7k indexed citations (citations by other indexed papers that have themselves been cited), including 931 papers in Genetics, 605 papers in Epidemiology and 405 papers in Surgery. Recurrent topics in Silvio Danese's work include Inflammatory Bowel Disease (924 papers), Microscopic Colitis (526 papers) and Eosinophilic Esophagitis (139 papers). Silvio Danese is often cited by papers focused on Inflammatory Bowel Disease (924 papers), Microscopic Colitis (526 papers) and Eosinophilic Esophagitis (139 papers). Silvio Danese collaborates with scholars based in Italy, France and United States. Silvio Danese's co-authors include Laurent Peyrin‐Biroulet, Claudio Fiocchi, Gionata Fiorino, William J. Sandborn, Bruce E. Sands, Jean‐Frédéric Colombel, Brian G. Feagan, Ferdinando D’Amico, Stefanos Bonovas and Remo Panaccione and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Silvio Danese

1.2k papers receiving 49.8k citations

Hit Papers

Vedolizumab as Induction and Maintenance Therapy for Ulce... 2007 2026 2013 2019 2013 2021 2017 2010 2020 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
    2013 2.0k citations Brian G. Feagan, Paul Rutgeerts et al. profile →
  2. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
    2021 1.5k citations Ferdinando D’Amico, William J. Sandborn et al. Gastroenterology profile →
  3. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
    2017 1.2k citations William J. Sandborn, Bruce E. Sands et al. profile →
  4. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
    2010 1.1k citations Jean‐Frédéric Colombel, Silvio Danese et al. Journal of Crohn s and Colitis profile →
  5. Ulcerative colitis
    2020 1.1k citations Britta Siegmund, Marc Ferrante et al. profile →
  6. Ulcerative Colitis
    2011 885 citations Silvio Danese et al. profile →
  7. Epithelial NEMO links innate immunity to chronic intestinal inflammation
    2007 871 citations Christoph Becker, Silvio Danese et al. profile →
  8. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
    2019 787 citations Bruce E. Sands, William J. Sandborn et al. profile →
  9. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial
    2016 738 citations Julián Panés, Jean‐Frédéric Colombel et al. profile →
  10. Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
    2013 685 citations Remo Panaccione, Silvio Danese et al. Gastroenterology profile →
  11. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
    2011 656 citations Silvio Danese et al. Gut profile →
  12. Crohn’s disease
    2020 631 citations Paulo Gustavo Kotze, Remo Panaccione et al. profile →
  13. The safety of vedolizumab for ulcerative colitis and Crohn's disease
    2016 563 citations Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut profile →
  14. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations
    2016 506 citations Silvio Danese et al. Journal of Crohn s and Colitis profile →
  15. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses
    2019 506 citations Silvio Danese, Laurent Peyrin‐Biroulet et al. Gastroenterology profile →
  16. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    2019 461 citations Bruce E. Sands, Laurent Peyrin‐Biroulet et al. profile →
  17. European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases
    2014 421 citations Silvio Danese, Fernando Magro et al. Journal of Crohn s and Colitis profile →
  18. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
    2021 335 citations William J. Sandborn, Brian G. Feagan et al. profile →
  19. Application of Artificial Intelligence to Gastroenterology and Hepatology
    2019 333 citations William J. Sandborn, Silvio Danese et al. Gastroenterology profile →
  20. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions
    2015 317 citations Laurent Peyrin‐Biroulet, Julián Panés et al. profile →
  21. Development and validation of the Nancy histological index for UC
    2015 303 citations Silvio Danese, S Schreiber et al. Gut profile →
  22. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
    2021 235 citations Silvio Danese, Laurent Peyrin‐Biroulet et al. profile →
  23. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
    2020 226 citations Silvio Danese, Laurent Peyrin‐Biroulet et al. Gastroenterology profile →
  24. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
    2019 212 citations William J. Sandborn, Silvio Danese et al. Gastroenterology profile →
  25. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
    2023 190 citations William J. Sandborn, Séverine Vermeire et al. profile →
  26. Inflammation and malnutrition in inflammatory bowel disease
    2023 155 citations Mariangela Allocca, Laurent Peyrin‐Biroulet et al. profile →
  27. Revisiting fibrosis in inflammatory bowel disease: the gut thickens
    2021 155 citations Silvia D’Alessio, Federica Ungaro et al. Nature Reviews Gastroenterology & Hepatology profile →
  28. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
    2022 132 citations William J. Sandborn, Geert D’Haens et al. Gastroenterology profile →
  29. Navigating the complexities of drug development for inflammatory bowel disease
    2024 47 citations Silvio Danese, Laurent Peyrin‐Biroulet et al. profile →
  30. Understanding the therapeutic toolkit for inflammatory bowel disease
    2025 35 citations Laurent Peyrin‐Biroulet, Marla C. Dubinsky et al. Nature Reviews Gastroenterology & Hepatology profile →

Peers

Silvio Danese
Comparison fields: 5 of 181
  • Genetics 30.1k
  • Epidemiology 20.9k
  • Surgery 13.2k
  • Immunology 12.3k
  • Molecular Biology 7.6k
Replace Laurent Peyrin‐Biroulet with:
Laurent Peyrin‐Biroulet France
Séverine Vermeire Belgium
Geert D’Haens Netherlands
Stefan Schreiber Germany
Jean‐Frédéric Colombel United States
Bruce E. Sands United States
Remo Panaccione Canada
Brian G. Feagan Canada
Gert Van Assche Belgium
Paul Rutgeerts Belgium
Laurent Peyrin‐Biroulet France View profile →
Citations per field, relative to Silvio Danese
Silvio Danese · 1×
Citations per year, relative to Silvio Danese
Silvio Danese · 1×

Countries citing papers authored by Silvio Danese

Since Specialization
Citations

This map shows the geographic impact of Silvio Danese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvio Danese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvio Danese more than expected).

Fields of papers citing papers by Silvio Danese

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvio Danese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvio Danese. The network helps show where Silvio Danese may publish in the future.

Co-authorship network of co-authors of Silvio Danese

This figure shows the co-authorship network connecting the top 25 collaborators of Silvio Danese. A scholar is included among the top collaborators of Silvio Danese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvio Danese. Silvio Danese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
DOP12 Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial
2024 ·Journal of Crohn s and Colitis ·Séverine Vermeire, Laurent Peyrin‐Biroulet, Silvio Danese, (unknown), Parambir S. Dulai, Herbert Tilg, Britta Siegmund, Paul Gineste, (unknown), Christian G. Rabbat, Bruce E. Sands
1
2
DOP64 Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trial
2024 ·Journal of Crohn s and Colitis ·Tim Raine, Silvio Danese, Stefan Schreiber, Xiang Gao, Stephen B. Hanauer, Joana Torres, Kristina Kligys, Xiu Huang, Ezequiel Neimark, (unknown), John Crowley, Raymond K. Cross
2
3
Are all the IL-23 blockers the same in inflammatory bowel disease?
2024 ·Nature Reviews Gastroenterology & Hepatology ·Silvio Danese, Laurent Peyrin‐Biroulet
4
4
DOP01 Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper
2024 ·Journal of Crohn s and Colitis ·Francesca Rosini, Roger Feakins, Paula Borralho, Ann Driessen, Ilyssa O. Gordon, Nina Zidar, Paméla Baldin, Britt Christensen, Silvio Danese, (unknown), Marietta Iacucci, Maurice B. Loughrey, Fernando Magro, Aart Mookhoek, Magali Svrcek
1
5
Multiple Ileal and Colonic Stenoses: Is It Always Crohn’s Disease?
2024 ·Journal of Crohn s and Colitis ·(unknown), Mariangela Allocca, Federica Furfaro, Ferdinando D’Amico, Tommaso Lorenzo Parigi, Silvio Danese, Alessandra Zilli
1
6
New Technologies in Digestive Endoscopy for Ulcerative Colitis Patients
2023 ·Biomedicines ·(unknown), Ferdinando D’Amico, (unknown), (unknown), F Bernardi, Mariangela Allocca, Alessandra Zilli, Silvio Danese, Federica Furfaro
9
7
P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023 ·Journal of Crohn s and Colitis ·Laurent Peyrin‐Biroulet, Marla C. Dubinsky, B E Sands, Julián Panés, S Schreiber, Walter Reinisch, B G Feagan, Silvio Danese, Andrés Yarur, Geert D’Haens, (unknown), (unknown), Joseph Wu, Irene Modesto, (unknown), (unknown), (unknown), Séverine Vermeire
4
8
P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials
2023 ·Journal of Crohn s and Colitis ·Séverine Vermeire, Laurent Peyrin‐Biroulet, Julián Panés, Miguel Regueiro, Paulo Gustavo Kotze, (unknown), (unknown), (unknown), Joseph Wu, (unknown), John Woolcott, Silvio Danese
9
9
The Management of Postoperative Recurrence in Crohn’s Disease
2023 ·Journal of Clinical Medicine ·(unknown), Ferdinando D’Amico, (unknown), Mariangela Allocca, Gionata Fiorino, Alessandra Zilli, Tommaso Lorenzo Parigi, Silvio Danese, Federica Furfaro
5
10
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
2023 ·Crohn s & Colitis 360 ·William J. Sandborn, Jingjing Chen, Krisztina Kisfalvi, Edward V. Loftus, Geert D’Haens, (unknown), Karen Lasch, Douglas C. Wolf, (unknown), Silvio Danese
6
11
Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn’s Disease and Ulcerative Colitis
2023 ·PharmacoEconomics - Open ·Edward V. Loftus, Ashwin N. Ananthakrishnan, Wan‐Ju Lee, Yuri Sánchez González, (unknown), Kori Wallace, Wen Zhou, Leighann Litcher‐Kelly, (unknown), (unknown), Silvio Danese
8
12
P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
2023 ·Journal of Crohn s and Colitis ·(unknown), Silvio Danese, Douglas C. Wolf, James B. Canavan, (unknown), (unknown), (unknown), Lorna Charles, (unknown), María T. Abreu
3
13
Gut virome in inflammatory bowel disease and beyond
2023 ·Gut ·Hein M. Tun, Ye Peng, Luca Massimino, (unknown), Tommaso Lorenzo Parigi, (unknown), Shaila Rahman, Silvio Danese, Federica Ungaro
39
14
Imaging in Gastroparesis: Exploring Innovative Diagnostic Approaches, Symptoms, and Treatment
2023 ·Life ·Francesco Vito Mandarino, Sabrina Gloria Giulia Testoni, Alberto Barchi, Francesco Azzolini, Emanuele Sinagra, (unknown), Arturo Chiti, Silvio Danese
13
15
Tu1717 SAFETY PROFILE OF RISANKIZUMAB IN CROHN'S DISEASE PATIENTS BY AGE: POST-HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES
2023 ·Gastroenterology ·Jean‐Frédéric Colombel, Silvio Danese, Naomi Martin, Kristina Kligys, (unknown), W. Rachel Duan, Yafei Zhang, (unknown), Remo Panaccione, Geert D’Haens, Marc Ferrante, Laurent Peyrin‐Biroulet
1
16
The Multiple Faces of Integrin–ECM Interactions in Inflammatory Bowel Disease
2021 ·International Journal of Molecular Sciences ·(unknown), Sara Lovisa, Silvio Danese, Stefania Vetrano
6
17
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer
2019 ·Cancer Research ·Carlotta Tacconi, Federica Ungaro, Carmen Correale, Vincenzo Arena, Luca Massimino, Michael Detmar, Antonino Spinelli, Michele Carvello, Massimiliano Mazzone, Ana I. Oliveira, Federica Rubbino, (unknown), (unknown), Enrico Lugli, Federico Colombo, Alberto Malesci, Laurent Peyrin‐Biroulet, Stefania Vetrano, Silvio Danese, Silvia D’Alessio
65
18
The safety of vedolizumab for ulcerative colitis and Crohn's disease breakdown →
2016 ·Gut ·Jean‐Frédéric Colombel, Bruce E. Sands, Paul Rutgeerts, William J. Sandborn, Silvio Danese, Geert D’Haens, Remo Panaccione, Edward V. Loftus, Serap Sankoh, Irving H. Fox, Asit Parikh, Catherine Milch, Brihad Abhyankar, Brian G. Feagan
563
19
Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1
2015 ·Cancer Research ·Roberta Mazzieri, Giovanni Pietrogrande, (unknown), Alessandro Gandelli, Piergiuseppe Colombo, Davide Moi, Chiara Brombin, Alessandro Ambrosi, Silvio Danese, Paolo Mignatti, Francesco Blasi, Silvia D’Alessio
10
20
Intestinal myofibroblast-specific Tpl2-Cox-2-PGE 2 pathway links innate sensing to epithelial homeostasis
2014 ·Proceedings of the National Academy of Sciences ·Manolis Roulis, Christoforos Nikolaou, Elena Kotsaki, Eleanna Kaffe, Niki Karagianni, Vasiliki Koliaraki, Klelia D. Salpea, Jiannis Ragoussis, Vassilis Aidinis, Eva Martini, Christoph Becker, Harvey R. Herschman, Stefania Vetrano, Silvio Danese, George Kollias
64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laurent Peyrin‐Biroulet Breakdown of academic impact, for papers by Séverine Vermeire Breakdown of academic impact, for papers by Geert D’Haens Breakdown of academic impact, for papers by Stefan Schreiber Breakdown of academic impact, for papers by Jean‐Frédéric Colombel Breakdown of academic impact, for papers by Bruce E. Sands Breakdown of academic impact, for papers by Remo Panaccione Breakdown of academic impact, for papers by Brian G. Feagan Breakdown of academic impact, for papers by Gert Van Assche Breakdown of academic impact, for papers by Paul Rutgeerts
Rankless by CCL
2026